Reality Check on HIV
Market access for HIV treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharamcy benefit, more than 75% of the covered lives in commercial formularies have utilization management restrictions
- Class Trends: Express Scripts Holding Co. added 48 new exclusions to its 2019 National Preferred Formulary, including Gilead Sciences, Inc.'s HIV drug Atripla
- Key Findings: Contracting is prevalent for drugs in the same HIV grouping, with most activity focused on tiering preference. Patent expirations are expected for single agents
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.